Principal Financial Group
AIMT

Principal Financial Group’s Aimmune Therapeutics AIMT Stock Holding History

Principal Financial Group’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,314
Closed -$700K – 2496
2020
Q3 		$700K Buy
20,314
+6,799
+50% +$145K ﹤0.01% 1940
2020
Q2 		$226K Buy
+13,515
New +$229K ﹤0.01% 2156
2020
Q1 		– Sell
-9,148
Closed -$306K – 2271
2019
Q4 		$306K Sell
9,148
-437
-5% -$12.2K ﹤0.01% 2050
2019
Q3 		$201K Buy
+9,585
New +$196K ﹤0.01% 2143
2019
Q2 		– Sell
-8,962
Closed -$200K – 2301
2019
Q1 		$200K Buy
8,962
+570
+7% +$13.4K ﹤0.01% 2120
2018
Q4 		$201K Sell
8,392
-8,631
-51% -$223K ﹤0.01% 2133
2018
Q3 		$464K Buy
17,023
+8,710
+105% +$246K ﹤0.01% 1973
2018
Q2 		$224K Sell
8,313
-769
-8% -$23.5K ﹤0.01% 2140
2018
Q1 		$289K Sell
9,082
-4,654
-34% -$164K ﹤0.01% 2031
2017
Q4 		$519K Buy
+13,736
New +$443K ﹤0.01% 1952

Principal Financial Group's AIMT Position: Q4 2020 in Review

Principal Financial Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 20,314 shares — an estimated $700K sold.

Principal Financial Group first reported a position in AIMT in Q4 2017 and held it in 10 quarters. The position peaked at $700K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Principal Financial Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Principal Financial Group sold 20,314 Aimmune Therapeutics shares in Q4 2020, an estimated $700K.
  • Principal Financial Group first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 10 quarters.
  • Principal Financial Group's Aimmune Therapeutics position peaked at $700K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Principal Financial Group's 13F filing for Q4 2020, filed 8 Feb 2021.